Fate of lymphocytes after withdrawal of tofacitinib treatment.

Tofacitinib (Tofa) is an inhibitor of Janus Kinase 3, developed for the treatment of autoimmune diseases and for the prevention of transplant rejection. Due to its selective action on proliferating cells, Tofa can offer a way to block T cell activation, without toxic effects on resting cells. Howeve...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Elisa Piscianz, Erica Valencic, Eva Cuzzoni, Sara De Iudicibus, Elisa De Lorenzo, Giuliana Decorti, Alberto Tommasini
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2014
Materias:
R
Q
Acceso en línea:https://doaj.org/article/c368fa2460f142dba23c19f4c39d15f0
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!